Friday, September 28, 2018 8:26:09 AM
RBII to Contract with Producers/Processors in MMJ States to License and Market Cannophen™, THC Products
SANDUSKY, Ohio, June 11, 2018 (GLOBE NEWSWIRE) -- (via OTC PR WIRE) – Rising Biosciences, Inc. (OTC:RBII) (“RBII” “the Company”), a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry, is pleased to announce that it is currently working with producers and processors in California, Arizona and Ohio to produce its products under licensing agreements with a target for end of September 2018 for the Company’s first products to hit dispensary shelves.
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM